Digestive Disease Week® 2021 to Showcase the TissueCypher® Barrett’s Esophagus Assay as a Paradigm-shifting Precision Medicine Tool
May 17, 2021 08:38 ET
|
Cernostics
Pittsburgh, Pennsylvania, May 17, 2021 (GLOBE NEWSWIRE) -- PITTSBURGH, Pennsylvania, May 17, 2021 – Cernostics (https://www.cernostics.com/) a pioneer in delivering spatialomics to the clinic,...
Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus
November 18, 2020 09:00 ET
|
Cernostics
Pittsburgh, PA, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Cernostics, Inc. the GI Precision Medicine company, today announced two newly completed clinical studies confirming the ability of the TissueCypher®...
Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease
July 01, 2019 09:00 ET
|
Cernostics
PITTSBURGH, PA, July 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Cernostics, developer of next-generation cancer diagnostics and prognostics, today announced the formation of a distinguished...
Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019
May 08, 2019 09:00 ET
|
Cernostics
PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use...
Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics
November 20, 2018 09:00 ET
|
Cernostics
US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics,...